Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02070029
Other study ID # 12053
Secondary ID
Status Completed
Phase N/A
First received January 26, 2014
Last updated October 15, 2014
Start date January 2013
Est. completion date June 2014

Study information

Verified date February 2014
Source TriHealth Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Female Sexual Dysfunction (FSD) affects up to 43% of women in the United States and Hypoactive Sexual Desire Disorder (HSDD) is the most common form. There is no standardized treatment for this condition. We know that alternative therapies such as acupuncture have been beneficial to women suffering from urinary incontinence, chronic lower back pain, and migraines. We hypothesize that the quality of life for premenopausal women with hypoactive sexual desire disorder (HSDD) will improve with initiation of acupuncture therapy for a duration of 5-weeks. Validated questionnaires are administered at the time of enrollment and 1 week after the final acupuncture session as the method of analyzing our primary outcome.


Description:

Each woman will receive experimental therapy with acupuncture twice a week for five weeks and complete a packet of validated questionnaires/surveys at the 1st visit in person and at week 6 by mail.

The acupuncture sessions include:

- An Initial Evaluation in which the certified acupuncturist will take a

- History including: chief complaint, diet, level of diaphoresis, water intake, digestive function, menstrual cycling, sleep habits, overall mood

- Physical Exam: inspection of tongue and palpation of pulse

- 25 minutes of resting quietly with acupuncture needles in place

- Needle usage: from8 to 20 needles are typically used, with an average of 14 per session

- Needles are typically placed on the scalp, lower abdomen, elbows and knees

Subsequent Sessions (9 more) with the certified acupuncturist

- 25 minute each, twice weekly, for 5 weeks = total 10 sessions

- Needle usage = 8-20, average 14 per session

- Typically placed on the scalp, lower abdomen, elbows and knees

The questionnaires/surveys include questions about:

- Sexual desire, arousal, lubrication, orgasm, satisfaction and pain

- General physical health

- General emotional and psychological health

- Social relationships


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date June 2014
Est. primary completion date June 2014
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Women aged 18-55 years

- Sexually Active

- Premenopausal

- Documented diagnosis of HSDD as primary cause of FSD (defined as a non adjusted score of = 6 in the desire domain of the FSFI questionnaire)

Exclusion Criteria:

- Postmenopausal, defined as absence of menstruation in the prior 12 months

- Pain or dyspareunia as the primary cause of FSD (defined as a non adjusted score of = 6 in the pain domain of the FSFI)

- History of hysterectomy and/or oophorectomy

- History of chemotherapy, or pelvic irradiation

- Use of hormonal contraception or oral hormone replacement therapy

- Active skin infection or disease

- Blood dyscrasia

- Allergy to acupuncture needles

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
Acupuncture
Acupuncture Therapy - Initial Evaluation History including: chief complaint, diet, level of diaphoresis, water intake, digestive function, menstrual cycling, sleep habits, overall mood. Physical Exam: inspection of tongue and palpation of central and peripheral pulses. Chinese Diagnoses for Female Sexual Dysfunction: Kidney Yang Deficiency; Liver Qi Stagnation; Generalized Blood Deficiency; Spleen Yang Deficiency; Heart Fire - Subsequent Sessions 25 minute sessions, twice weekly, for 5 weeks = total 10 sessions Needle usage = 8-20, average 14 per session Typically placed on the scalp, lower abdomen, elbows and knees

Locations

Country Name City State
United States TriHealth Cincinnati Ohio

Sponsors (2)

Lead Sponsor Collaborator
TriHealth Inc. TriHealth Medical Education Research Fund

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Female Sexual Function Index (FSFI) Determined by a change in the desire domain of the Female Sexual Function Index (FSFI) from baseline at enrollment to study completion at 6 weeks after initiation of intervention. 6 weeks No
Secondary Female Sexual Distress Scale (FSDS-R) Determined by functional data points distributed at enrollment and 6 weeks:
Female Sexual Distress scale - revised (FSDS-R)
6 weeks No
Secondary Short Form-12 (SF-12) Determined by functional data points distributed at enrollment and 6 weeks:
Short Form-12 (SF-12)
6 weeks No
Secondary Generalized Anxiety-Disorder-7 (GAD-7) and Prime Health Questionnaire-9 (PHQ-9) Determined by functional data points distributed at enrollment and 6 weeks:
Generalized Anxiety-Disorder-7 (GAD-7) and Prime Health Questionnaire-9 (PHQ-9)
6 weeks No
Secondary World Health Organization Quality of Life- BREF (WHOQOL) Determined by functional data points distributed at enrollment and 6 weeks:
World Health Organization Quality of Life- BREF (WHOQOL)
6 weeks No
Secondary Patient Global Impression of Improvement (PGI-I) Determined by functional data points distributed at enrollment and 6 weeks:
Patient Global Impression of Improvement (PGI-I)
6 weeks No
See also
  Status Clinical Trial Phase
Withdrawn NCT03619005 - Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study Phase 3
Completed NCT03080298 - Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire Phase 2
Completed NCT00349791 - Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido Phase 3
Completed NCT01702818 - Stress Hormones, Mood and Women's Sexual Desire (MODEST)